
Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-... Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. Show more
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.26 | -3.77906976744 | 6.88 | 7.03 | 5.935 | 3014873 | 6.54779494 | CS |
4 | -2.28 | -25.6179775281 | 8.9 | 9.545 | 5.935 | 2790159 | 7.67489947 | CS |
12 | -11.22 | -62.8923766816 | 17.84 | 20.3762 | 5.935 | 2139082 | 11.18656579 | CS |
26 | -17.88 | -72.9795918367 | 24.5 | 29.6106 | 5.935 | 1403615 | 14.53653128 | CS |
52 | -29.67 | -81.7580600716 | 36.29 | 39.34 | 5.935 | 1060516 | 19.39740058 | CS |
156 | -58.92 | -89.8992981385 | 65.54 | 69.73 | 5.935 | 706484 | 27.78276129 | CS |
260 | -39.32 | -85.5898998694 | 45.94 | 108.465 | 5.935 | 641133 | 39.22863326 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales